Physician profile
Ryan Vern Miller
NPI 1740243823
$1,061.64
in general payments reported to CMS, 2019-2025
11 companies · $69.07 in 2025
The $69.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.95 · 2020: $13.82 · 2021: $381 · 2022: $308 · 2023: $209 · 2024: $41.76 · 2025: $69.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.62 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $196.16 | 2021-2023 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $188.67 | 2021-2023 | Eliquis |
| Pfizer INC. | $164.34 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $79.73 | 2019-2023 | Brilinta |
| Abbott Laboratories | $75.98 | 2023 | Jot Dx |
| Alnylam Pharmaceuticals INC. | $29.30 | 2025 | |
| Baxter Healthcare | $26.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.74 | 2025 | Caplyta |
| Amarin Pharma, INC. | $16.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.